Filtered By:
Condition: Hemorrhagic Stroke
Education: Study
Management: Economics

This page shows you your search results in order of date.

Order by Relevance | Date

Total 15 results found since Jan 2013.

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients
ConclusionsThe use of a blood biomarker test to guide pre-hospital thrombolysis is cost-effective compared with standard hospital care in patients with ischemic stroke.
Source: The European Journal of Health Economics - July 27, 2022 Category: Health Management Source Type: research

Risk of delirium and impaired neurological outcome associated with delay in neurorehabilitation after acquired brain injury - Hansen PM, Lauridsen JT, Frandsen NS.
INTRODUCTION Brain injury from haemorrhage, trauma, aneurysm and stroke is characterised by high mortality and impaired neurological outcome. In the OUTREACH study, the authors wanted to assess patient care from admission to intensive neuro rehabilitation ...
Source: SafetyLit - September 27, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

The IMPact of UntReated NOn-Valvular Atrial Fibrillation on Short-TErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model
CONCLUSION: Our findings suggest that increased overall OAC use has a positive clinical benefit on the annual number of ischemic stroke events and deaths avoided in the Medicare population, while maintaining a modest increase in the overall BI to the Medicare system.PMID:34415229 | DOI:10.1080/13696998.2021.1970954
Source: Journal of Medical Economics - August 20, 2021 Category: Health Management Authors: Matthew Sussman Manuela Di Fusco Charles Y Tao Jennifer D Guo John A Gillespie Mauricio Ferri Nicholas Adair Matthew S Cato Ilnaz Shirkhorshidian Geoffrey D Barnes Source Type: research

Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
CONCLUSIONS: The NNT calculation, when approached and interpreted properly, is a practical measure of the effectiveness of a treatment. The calculation based on HRs showed that NOACs are safe and effective alternatives to VKAs in real life. PMID: 30969801 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 12, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The weekend effect revisited: evidence from the Upper Austrian stroke registry
AbstractEmpirical evidence on the so-called ‘weekend-effect’ on stroke mortality is mixed with some studies reporting significantly higher mortality for weekend admissions and others finding no difference. The aim of this paper is to enhance the evidence on the weekend-effect on stroke mortality using a rich stroke registry data set from Upper Austria and to discuss underlying reasons for the heterogeneity in results. Using logistic regressions and ordinary least squares regressions with hospital and year-fixed effects, the outcomes of weekend versus weekday admissions are compared for patients admitted to 16 hospitals...
Source: The European Journal of Health Economics - February 12, 2019 Category: Health Management Source Type: research

Estimating lifetime medical costs from censored claims data
In this study, we propose a survival‐adjusted estimator for estimating mean lifetime costs, which integrates the product of the survival function and the mean cost function over the lifetime horizon. The survival function is estimated by a new algorithm of rolling extrapolation, aided by external information of age‐ and sex‐matched referents simulated from national vital statistics. The mean cost function is estimated by a weighted average of mean expenditures of patients in a number of months prior to their death, of which the number could be determined by observed costs in their final months, and the weights depend...
Source: Health Economics - May 12, 2017 Category: Health Management Authors: Jing ‐Shiang Hwang, Tsuey‐Hwa Hu, Lukas Jyuhn‐Hsiarn Lee, Jung‐Der Wang Tags: RESEARCH ARTICLE Source Type: research

4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news

Needs of Internally Displaced Women and Children in Baghdad, Karbala, and Kirkuk, Iraq
Conclusions The vulnerability of this population is great, and the emotional trauma of multiple displacements, kidnapping and deaths from intentional violence is great. While some aid is reaching families, much more is needed. Though Iraq is a middle income country, reaching the IDPs in central Iraq will take much more in international assistance than is currently being received. Unfortunately, at this time of great need, assistance is being cut back throughout the region because of lack of funding.10 The local civil society organizations which have sprung up in many locations to assist IDPs, offer an avenue for targeting ...
Source: PLOS Currents Disasters - June 10, 2016 Category: Global & Universal Authors: Gilbert Burnham Source Type: research

Economic impact of patients admitted to stroke units in Spain
Conclusions The cost of patients admitted to stroke units in Spain is €27,711 per patient/year. More than two-thirds are social costs, mainly informal care. Stroke remains a major burden on health systems and society, so additional efforts are needed for its prevention.
Source: The European Journal of Health Economics - April 14, 2016 Category: Health Management Source Type: research

Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation
Conclusions Real-world Canadian data and a phase-based costing approach were used to estimate short- and long-term costs associated with AF-related major clinical events. The results of this study can also inform decision–analytic models for AF.
Source: Applied Health Economics and Health Policy - February 29, 2016 Category: Health Management Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research